The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets
- 25 July 2014
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 16 (11) , 937-941
Abstract
Breast cancers and most malignant tumors are composed of heterogeneous tumor cells both at genetic and morphological levels; intra-tumor heterogeneity can be one underlying cause of therapeutic resistance. Classical studies have focused on analyses of the relationship between primary tumors and metastatic dissemination, and on subclone evolution. However, it should be noted that tumor heterogeneity at the level of protein expression (proteomics) has not been yet studied in depth. The differences in protein expression also can play an important role in elucidating the relationship between intra-tumor heterogeneity and resistance to systemic therapy. In fact, in human tumors there is not always a homogeneous expression of many of the crucial factors involved in cell signaling, such as pMAPK, pAKt, pMTOR, even with constitutive oncogenic alterations upstream, such as HER2, PI3 K. Conversely, two of these factors, peIF4E and p4E-BP1, which are downstream, and control protein translation, show a diffuse and strong protein expression. In summary, most of cell signaling factors show a heterogeneous expression, regardless of oncogenic alterations. Tissue heterogeneity could be driven by local factors, including hypoxia. The fact that the phosphorylation of crucial proteins such as 4E-BP1 and eIF4E is observed homogeneously throughout most tumors and are druggable opens the chance to get real potential targets in cancer therapy.Keywords
This publication has 14 references indexed in Scilit:
- Genome evolution during progression to breast cancerGenome Research, 2013
- Intratumor Heterogeneity: Evolution through Space and TimeCancer Research, 2012
- The Life History of 21 Breast CancersCell, 2012
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersNature, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Research, 2011
- Tumour evolution inferred by single-cell sequencingNature, 2011
- 4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical ImplicationsCancer Research, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Molecular portraits of human breast tumoursNature, 2000